Clinical trials: Mental Disorder
Schizophrenia
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
This is a Phase 3b, 3-year, open-label, multi-center study in which patients with DSM-5 diagnosis of schizophrenia whose current medication(s) is not well tolerated and/or clinical symptoms are not well controlled will be…
- Trial name
- PENNANT (NCT05643170)
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Fragile X Syndrome
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
The study objective is to explore the efficacy, safety and tolerability of STX209 for treatment of irritability in subjects with FSX.
- Trial name
- NCT00788073
- Testing
- STX209
- Where
- 12 sites in United States
- Volunteers
- 63 people
- Sponsor
- Seaside Therapeutics, Inc.
Depressive Disorder, Major
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.
- Trial name
- NCT01152996
- Testing
- Vortioxetine
- Volunteers
- 1,075 people
- Sponsor
- Takeda
Depressive Disorder, Major
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
- Trial name
- NCT00445679
- Testing
- DVS SR, Paroxetine
- Where
- 43 sites in China, India and 2 more
- Volunteers
- 807 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Generalized Anxiety Disorder
A Study of Duloxetine in Elderly Generalized Anxiety Disorder
The purpose of this study is to test the safety and efficacy of duloxetine versus placebo in elderly patients suffering from generalized anxiety disorder (GAD).
- Trial name
- NCT01118780
- Testing
- Duloxetine
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Alcohol Use Disorder
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
This study will determine the maximum tolerated dose (MTD) of arbaclofen placarbil (AP) in the treatment of subjects with Alcohol Use Disorder (AUD). For every two subjects receiving AP, one subject will receive placebo.
- Trial name
- NCT02511886
- Testing
- Arbaclofen Placarbil
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indivior Inc.
Alcohol Dependence
A Study for the Treatment of Alcohol Dependence
The Primary objective of this study is to test whether LY2196044 can reduce the number of heavy drinking days per month in people with alcohol dependence.
- Trial name
- NCT00804570
- Testing
- LY2196044
- Where
- 17 sites in United States
- Volunteers
- 375 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major…
- Trial name
- NCT00388973
- Testing
- Quetiapine
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 338 people
- Sponsor
- AstraZeneca
Smokers
Nicotine Patch Safety Study
The purpose of this study is to evaluate the safety profile of a repeated application of a new transdermal patch compared to a reference product during 3 weeks, in a large population.
- Trial name
- NCT01655082
- Testing
- V0116 transdermal patch, Nicotine transdermal patch
- Where
- 4 sites in France
- Volunteers
- 160 people
- Sponsor
- Pierre Fabre Medicament
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
This randomized, double-blind, placebo- and active-controlled, parallel group study will evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute exacerbation of schizophrenia.
- Trial name
- NCT01234779
- Testing
- bitopertin [RO4917838], olanzapine
- Where
- 46 sites in United States, Romania and 3 more
- Volunteers
- 301 people
- Sponsor
- Hoffmann-La Roche
Neonatal Abstinence Syndrome
Study to Collect Data for Neonatal Abstinence Syndrome (NAS) and Evaluate the Automated Data Collection Process
Substance abuse during pregnancy is on the rise through both prescribed and illicit use of controlled substances, which has increased neonatal abstinence syndrome (NAS).
- Trial name
- NCT06303986
- Testing
- NeoMonki
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Rekovar Inc.
Restless Legs Syndrome
Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome
Prospective multi-site randomized sham-controlled crossover feasibility study evaluating tolerability and efficacy of noninvasive peripheral nerve stimulation (NPNS) for patients with moderate-severe primary Restless Legs…
- Trial name
- NCT04700683
- Testing
- Noctrix Health NPNS device v1.0 - Active
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Noctrix Health, Inc.
Alzheimer's Disease
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort
This study consists of 2 periods: [1] Study Period A - evaluating the efficacy and safety of Crenezumab versus Placebo in participants who carry the PSEN1 E280A autosomal-dominant mutation and do not meet the criteria for mild…
- Trial name
- NCT01998841
- Testing
- Crenezumab
- Where
- 4 sites in Colombia
- Volunteers
- 252 people
- Sponsor
- Genentech, Inc.
Depression, Depressive Disorder
A Treatment for Depression Via a Gamified Mobile Phone Application Based on a New Cognitive Model
The study is a randomized controlled treatment study comparing changes in depressive symptoms over 8 weeks between individuals with Major Depressive Disorder (MDD) who have access to an FTP-based mobile phone application and a…
- Conditions
- Depression, Depressive Disorder, Clinical Depression, Major Depressive Disorder
- Trial name
- FTP (NCT05685758)
- Testing
- FTP-based therapeutic mobile-app
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Hedonia Ltd
Opioid Use Disorder
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Extended-release buprenorphine (SUBLOCADE®) injection is currently approved for subcutaneous administration in the abdomen for treatment of opioid use disorder (OUD).
- Trial name
- NCT05704543
- Testing
- Buprenorphine Extended-Release Injection
- Where
- 6 sites in United States
- Volunteers
- 132 people
- Sponsor
- Indivior Inc.
Laryngopharyngeal Reflux
Predictive Value of Subjective and Objective Measurement Tools for Extraesophageal Reflux
Acid reflux can cause many symptoms in the throat, including discomfort or pain, and difficulty with breathing and voice problems.
- Trial name
- NCT01829074
- Volunteers
- 150 people
- Sponsor
- Respiratory Technology Corporation
Nocturnal Enuresis
PureWick™ France and U.S. At-Home Pilot Study
In this prospective, post-market, multi-site, open-label, crossover trial, women with urinary incontinence requiring the use of diapers (changes complets (French term)) at night will be 1:1 randomized to a treatment sequence…
- Trial name
- NCT05710718
- Testing
- PureWick™ System, Hollister® Female Urinary Pouch External Collection Device
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- C. R. Bard
PTSD
7-Keto DHEA for the Treatment of PTSD
The purpose of this research study is to test the effectiveness of 7-Keto DHEA in reducing symptoms of Post-Traumatic Stress Disorder (PTSD).
- Trial name
- NCT01861847
- Testing
- 7-Keto Dehydroepiandrosterone
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Humanetics Corporation
Major Depressive Disorder
Study of ALTO-300 in MDD
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
- Trial name
- NCT05922878
- Testing
- ALTO-300
- Where
- 75 sites in United States
- Volunteers
- 325 people
- Sponsor
- Alto Neuroscience
Major Depressive Disorder
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
The primary objective of this study is to assess whether LY2216684 12 milligrams (mg) or 18 mg flexible dose once daily is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder…
- Trial name
- NCT01185340
- Testing
- LY2216684, SSRI
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 1,056 people
- Sponsor
- Eli Lilly and Company
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.